DOCSLIB.ORG

Fentanyl and Its Analogues - 50 Years On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fentanyl and Its Analogues - 50 Years On 17 GLOBAL March S MART UPDATE VOLUME VOLUME Fentanyl and its analogues - 50 years on Research 2017 GLOBAL SMART UPDATE About the SMART Update Content Synthetic drugs constitute one of the most significant SPECIAL SEGMENT 3 drug problems worldwide. After cannabis, amphet- amine-type stimulants (ATS) are the second most widely used drugs across the globe, with use levels SHORT SEGMENTS 8 often exceeding those of heroin and/or cocaine. Along BEIJING, China – September 2015 with ATS, the continued growth of thenew psychoactive 8 substances (NPS) market over the last years has become BEIJING, China – May 2015 8 a policy challenge and a major international concern. A growing interplay between these new drugs and tra- TOKYO, Japan – August 2016 8 ditional illicit drug markets is being observed. By July 2016, the emergence of NPS had been reported from HELSINKI, Finland – June 2015 8 102 countries and territories. Trends on the synthetic drug market evolve quickly each year. STOCKHOLM, Sweden – August 2016 9 The UNODC Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) Programme enhances TALLINN, Estonia – July 2016 9 the capacity of Member States in priority regions to VIENNA, Austria – May 2016 generate, manage, analyse, report and use synthetic 9 drug information to design effective policy and pro- VIENNA, Austria – November 2016 9 gramme interventions. Launched in September 2008, the Global SMART Programme provides capacity building GENEVA, Switzerland – November 2016 10 to laboratory personnel, law enforcement and research officers in the Pacific, East and South-East Asia, South BRUSSELS, Belgium – 2015 10 Asia, the Near and Middle East, Africa and Latin America; and regularly reviews the global amphetamine-type DUBLIN, Ireland – 2016 10 stimulants andnew psychoactive substances situation. Its main products include online drug data collection, SÃO PAULO, Brazil – September 2016 10 situation reports, regional assessments and the UNODC Early Warning Advisory (EWA) on new psychoactive OTTAWA, Canada – September 2016 11 substances. The EWA is a webportal that offers regu- lar updates on new psychoactive substances, including LOS ANGELES, California – March 2016 11 trend data on emergence and persistence, chemical data, supporting documentation on laboratory analysis BRITISH COLUMBIA, Canada – June 2016 11 and national legislative responses (available at: www. WASHINGTON D.C., United States – 2016 11 unodc.org/NPS). The Global SMART Update (GSU) series is published twice a year in English, Spanish and Russian and provides information on emerging patterns and trends of the global synthetic drug situation in a concise format. Each issue of the Global SMART Update contains a special segment and short segments on the topic of interest.* Electronic copies of the Global SMART Updates and other publications are available at: www.unodc.org/ unodc/en/scientists/publications-smart.html. Past issues have covered topics such as UNGASS 2016 recommenda- tions, injecting use of synthetic drugs, legal responses to NPS, key facts about synthetic cannabinoids and regional patterns of methamphetamine manufacture. * The information and data contained within this report are from official Government reports, press releases, scientific journals or incidents confirmed by UNODC Field Offices. An asterisk (*) indicates that information is preliminary as it stems from ‘open sources’ where UNODC is waiting for official confir- mation. This report has not been formally edited. The contents of this publication do not necessarily reflect the views or policies of UNODC or contributory organizations and neither do they imply any endorsement. Suggested citation: UNODC, Global SMART Update Volume 17, March 2017. 2 Volume 17 Fentanyl and its analogues - 50 years on ABSTRACT Fentanyl is the strongest opioid Fentanyl and its analogues are potent synthetic opioids, which are available for medical use in humans, with about 100 times the potency of liable to abuse. They are often sold under the guise of heroin or morphine2. It is highly valued for its prescription medicines, such as oxycodone, and this exacerbates analgesic and sedative effects and the risk of overdose and associated fatalities. An increasing num- widely used in the management of ber of deaths have been associated with the use of fentanyl and severe pain and in anaesthesia. The its analogues, particularly in North America. The facile synthesis of three fentanyl analogues approved a number of these substances, coupled with the ease in obtaining for pharmaceutical use, sufentanil, alfentanil and remifentanil, have the required precursor chemicals and equipment, has led to an very short onset and duration of SEGMENT SPECIAL increase in clandestine manufacture. action, and their medical use is lim- ited to intravenous anaesthesia3. Introduction Carfentanil, estimated to be about 10,000 times more potent than Recent years have seen a sharp rise and fentanyl analogues. Evidence on morphine4, is intended only for vet- in opioid-related overdose deaths fatalities associated with emerging erinary use on large animals, and not mainly in North America, and to a fentanyl analogues is accumulating, approved for medical use in humans. certain extent, in Europe. While the also, in other regions of the world. challenge posed by these fatalities The pills and powders containing The liability of fentanyl and its is complex, more evidence is emerg- such substances sold on the illicit analogues to abuse and the depen- ing about the role fentanyl and its market pose a threat to public health dence-potential are reflected in the analogues play in the current crisis. because of the variable quantity and international legislative responses. Fentanyl itself is a powerful opioid potency of the active components, Fentanyl was first synthesized in analgesic, with an established place which in extreme cases, such as with 1959, and was placed under inter- national control as a Schedule 1 in medicine. Yet, there has always carfentanil, may be 10,000 times substance in 1964 under the Single been concern about its potential for more potent than morphine. Such Convention on Narcotic Drugs of abuse and dependence, and it was products can prove particularly dan- 1961. During the ensuing decades, therefore placed under international gerous when sold as street heroin, together with heroin or as counter- the list of scheduled substances control as far back as 1964. In the has grown to include all fentanyl 1970s and 1980s, products con- feit prescription drugs, without the user’s knowledge. analogues approved for human taining fentanyl and its analogues medical use (sufentanil in 1980, appeared on the illicit drug market, This publication aims to inform alfentanil in 1984, and remifentanil and became notorious for accidental about the growing complexity of the 1 in 1999), and several analogues overdoses. The problem seems to opioid market, in particular the fen- which have not been developed have resurfaced and the clandes- tanyl group, international controls, into pharmaceutical products tine manufacturing of fentanyl has evolving patterns of use and associ- (acetyl-alpha- methylfentanyl, alpha- risen to unprecedented levels. The ated risks, global developments in methylfentanyl and 3-methylfentanyl required materials and equipment manufacture and trafficking of fen- were placed under international for manufacture are readily available tanyl analogues and their precursors. control in 1988, and alpha-methyl- online, at low cost. This situation is thiofentanyl, beta-hydroxyfentanyl, aggravated by the rapid emergence Good medicines, beta-hydroxy-3-methylfentanyl, of novel fentanyl analogues which bad drugs? 3-methylthiofentanyl, para-fluoro- have not been approved for medi- Fentanyl belongs to a class of potent fentanyl and thiofentanyl in 1990). cal use. opioid analgesics, the 4-anilidopi- North America is particularly affected peridines. These synthetic opioids by an opioid overdose crisis. While have a high affinity for theµ -opioid originally, the sharp rise in over- receptor, which presents both bene- doses was attributed to heroin, the fits and drawbacks. On the one hand, current crisis is mainly attributed to strong µ-opioid receptor agonists 2 Chodoff P, Domino EF. Comparative phar- macology of drugs used in neuroleptanalge- clandestinely manufactured fentanyl from the fentanyl family have excel- sia. Anesthesia and Analgesia, 44 (5) (1965), lent pain-relieving properties. On the pp. 558–563 other hand, such drugs are liable to 3 Lemmens H. Pharmacokinetic-pharmaco- abuse and have high dependence- dynamic relationships for opioids in bal- producing properties. anced anaesthesia. Clin Pharmacokinet. 1 Henderson GL. Fentanyl-related deaths: 1995;29:231–242. demographics, circumstances, and toxicology 4 Janssen PA. Potent, new analgesics, tailor- of 112 cases. Journal of Forensic Science. made for different purposes. Acta Anaesthe- 1991 Mar 1;36(2):422-33. siol Scand. 1982 Jun;26(3):262-8. 3 GLOBAL SMART UPDATE Figure 1: International control of fentanyl and its analogues, 1964-2016 Fentan eport the UNODC Early Warning Advisory acrletanl para-fluoroisobutyrfentanyl 2016 butyrfentanyl, furanylfentanyl 2015 eletanl eletanl oetanl 2013 remetl 1999 1990 1988 alphamethloetanl beta-hydroxyfetanl beta-hydroxymethletanl methloetanl para-fluorofentanyl, thiofentanyl 1984 letl elalphamethletanl alphamethletanl methletanl 1980 uetl 1964 Fentan ontr fetanl 1961 Single Convention on Narcotic Drugs Acetylfentanyl was placed under
Load more

Recommended publications
  • A Review of Synthetic Fentanyl Metabolism and the Metabolism of Select Synthetic Fentanyl Analogues
    A review of synthetic fentanyl metabolism and the metabolism of select synthetic fentanyl analogues Gerard Lee A thesis submitted for the completion of a degree in Master of Forensic Science (Professional Practice) in The School of Veterinary and Life Sciences Murdoch University Supervisors: Associate Professor James Speers (Murdoch) Associate Professor Bob Mead (Murdoch) Semester 1, 2019 i Declaration I declare that this thesis does not contain any material submitted previously for the award of any other degree or diploma at any university or other tertiary institution. Furthermore, to the best of my knowledge, it does not contain any material previously published or written by another individual, except where due reference has been made in the text. Finally, I declare that all reported experimentations performed in this research were carried out by myself, except that any contribution by others, with whom I have worked is explicitly acknowledged. ii Acknowledgements I would like to thank my supervisor Bob Mead for his time guiding me and providing feedback on this endeavour. He has been a great help providing insights and advice from when I started university at Murdoch until now for which I am extremely grateful. To James Speers, thank you for helping me find a direction for this project when I started out. And finally, to my family and friends for their encouragement and support. iii Table of Contents Title page. ...............................................................................................................................I
    [Show full text]
  • Perioperative Opioid-Sparing Analgesia Strategies for Enhanced Recovery After Surgery
    Perioperative Opioid-Sparing Analgesia Strategies for Enhanced Recovery After Surgery T. Anthony Anderson, MD PhD Associate Professor Department of Anesthesiology, Perioperative and Pain Medicine Lucile Packard Children's Hospital Stanford Stanford University School of Medicine International Society for Anaesthetic Pharmacology 2018 Annual Meeting Disclosures • I have no relevant relationships to disclose Learning Objectives After this lecture, the listener should be able to: • Identify risks associated with the perioperative use of opioids • Determine opioid-sparing systemic pharmacologic analgesics options • Organize a perioperative analgesic plan to decrease postoperative pain, reduce opioid use, hasten recovery, and improve patient safety Paradigm Shift Surgical Considerations Optimize Co-Morbidities Baseline Pain & Opioid Use Regional techniques Non-pharmacologic Non-opioid Opioids Reasons to Reduce Peri-operative Opioid Use • Relapse risk in patients with a history of opioid use disorder • Improved post-operative recovery • Acute risks • Chronic risks Opioid Use Disorder Relapse • In 2016, 1.8 million people had prescription pain medication use disorder, 5.5% of population • High risk group • Poor evidence for pain management options • Perioperative exposure to relapse triggers: – Stress – Agent of abuse Ward EN, Quaye AN, Wilens TE. Opioid Use Disorders: Perioperative Management of a Special Population. Anesth Analg. 2018 Aug;127(2):539-547. Briand LA, Blendy JA. Molecular and genetic substrates linking stress and addiction. Brain Res. 2010 Feb 16;1314:219-34. ERAS Colorectal Surgery • 13 major perioperative categories • 3 rely heavily on opioid reduction – Multimodal, opioid-sparing pain management – PONV prevention – Ileus reduction • ERAS protocols reduce – Length of hospital stay – Costs – Minor complications Carmichael JC, Keller DS, Baldini G, Bordeianou L, Weiss E, Lee L, Boutros M, McClane J, Feldman LS, Steele SR.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Original Article Anesthetic Effect of Propofol Combined with Remifentanil and Propofol Combined with Ketamine in Ophthalmic Surgery
    Int J Clin Exp Med 2019;12(7):9387-9392 www.ijcem.com /ISSN:1940-5901/IJCEM0079428 Original Article Anesthetic effect of propofol combined with remifentanil and propofol combined with ketamine in ophthalmic surgery Xiaofeng Yi1*, Yanbing Zhang1*, Limin Jin1, Xinjing Yang2 Departments of 1Anesthesia Surgery, 2Emergency ICU, First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China. *Equal contributors. Received May 10, 2018; Accepted December 7, 2018; Epub July 15, 2019; Published July 30, 2019 Abstract: Propofol combined with ketamine has been used for anesthesia in the past. Remifentanil presented a good analgesic effect, rapid onset, short half-life, and a high clearance rate. Propofol combined with remifentanil also shows good effects in the clinic. This study compared the effect and safety of propofol combined remifentanil and propofol combined ketamine in pediatric eye surgery. Pediatric patients that received eye surgery in our hospital were selected and randomly divided into two groups, the experimental group (n=30), in which patients received pro- pofol combined with remifentanil anesthesia and control group (n=30), and the group receiving propofol combined with ketamine anesthesia. The curative effect, FCO2, SPO2, MAP, HR, anesthesia complications, operation time, recovery time, and leaving PACU time were compared. The rate of good anesthesia was 93.33% in the experimental group, which was significantly higher than control (P < 0.05). FCO2 at 2 and 5 minutes after anesthesia, preopera- tive, intraoperative, and postoperative elevated, while SPO2, MAP, and HR decreased (P < 0.05). The experimen- tal group showed smaller fluctuation range than the control. The rate of Nausea (6.67%), vomiting (3.33%), and somnolence (10%) in the experimental group was significantly lower than control (P < 0.05).
    [Show full text]
  • Federal Register/Vol. 85, No. 36/Monday, February 24, 2020
    10466 Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices Controlled substance Drug code Schedule Alphamethadol ................................................................................................................................................................. 9605 I Benzethidine .................................................................................................................................................................... 9606 I Betacetylmethadol ........................................................................................................................................................... 9607 I Clonitazene ...................................................................................................................................................................... 9612 I Diampromide ................................................................................................................................................................... 9615 I Diethylthiambutene .......................................................................................................................................................... 9616 I Dimethylthiambutene ....................................................................................................................................................... 9619 I Ketobemidone .................................................................................................................................................................
    [Show full text]
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • Analysis of Synthetic Opioids in Postmortem Blood, Vitreous Humor, and Brain Tissue
    City University of New York (CUNY) CUNY Academic Works Student Theses John Jay College of Criminal Justice Fall 12-2018 Analysis of synthetic opioids in postmortem blood, vitreous humor, and brain tissue Rachel K. Chesser CUNY John Jay College, [email protected] How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/jj_etds/88 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] i Analysis of synthetic opioids in postmortem blood, vitreous humor, and brain tissue A thesis presented in partial fulfillment of the requirements for the degree of Master of Science in Forensic Science John Jay College of Criminal Justice City University of New York Rachel Chesser December 2018 ii Analysis of synthetic opioids in postmortem blood, vitreous humor, and brain tissue Rachel Chesser This thesis has been presented to and accepted by the Office of Graduate Studies, John Jay College of Criminal Justice in partial fulfillment of the requirements for the degree of Master of Science in Forensic Science. Thesis Committee Thesis Advisor: Dr. Marta Concheiro-Guisan Second Reader: Dr. Gail Cooper External Reader: Dr. Luke N. Rodda iii Acknowledgements I would like to express my sincerest gratitude to Dr. Marta Concheiro, my advisor, for providing her guidance towards my thesis research and providing me with a strong background on forensic toxicology that allowed me to complete my project. She has been so patient and helpful with me in putting my thesis together and helping me make sense of it for parts I did not understand.
    [Show full text]
  • 2015-02 Toxicology Rapid Testing Panel
    SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Food and Drug Administration 5630 Fishers Lane, Rm
    Sent via Electronic and U.S. Mail October 13, 2015 James R. Hunter Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-N-0045 for International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Ketamine; Phenazepam; Etizolam; 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine (MT-45); N-(1-Phenethylpiperidin- 4-yl)-N-phenylacetamide (Acetylfentanyl); α-Pyrrolidinovalerophenone (α-PVP); 4- Fluoroamphetamine (4-FA); para-Methyl-4-methylaminorex (4,4’-DMAR); para- Methoxymethylamphetamine (PMMA); 2-(ethylamino)-2-(3-methoxyphenyl)- cyclohexanone (Methoxetamine or MXE); Request for Comments Dear Mr. Hunter: This letter responds to the Food and Drug Administration’s (FDA) request for comments that appeared in the Federal Register on October 5, 2015, concerning International Drug Scheduling. The Association of Public and Land-grant Universities (APLU) represents 237 public research universities, land-grant institutions, state university systems, and affiliated organizations. Many of our member institutions have veterinary and medical schools and nearly all our institutions have researchers and students who conduct biomedical research. On behalf of our institutional membership, APLU appreciates this opportunity to provide the FDA with comments. APLU strongly objects to any attempt to alter the international regulation of ketamine that would result in increased difficulty for biomedical researchers to use this drug for legitimate and appropriate treatments. The United States currently classifies ketamine as a Schedule III drug under the Controlled Substance Act (CSA). As such, strict regulations and safeguards are already in place to prevent its illegal use. As known to FDA, Schedule I drugs are defined as those with no currently acceptable medical use, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
    [Show full text]
  • A Review of Unique Opioids and Their Conversions
    A Review of Unique Opioids and Their Conversions Jacqueline Cleary, PharmD, BCACP Assistant Professor Albany College of Pharmacy and Health Sciences Adjunct Professor SAGE College of Nursing DISCLOSURES • Kaleo • Remitigate, LLC OBJECTIVES • Compare and contrast unique pharmacotherapy options for the treatment of chronic pain including: methadone, buprenoprhine, tapentadol, and tramadol • Select methadone, buprenorphine, tapentadol, or tramadol based on patient specific factors • Apply appropriate opioid conversion strategies to unique opioids • Understand opioid overdose risk surrounding opioid conversions and the use of unique opioids UNIQUE OPIOIDS METHADONE, BUPRENORPHINE, TRAMADOL, TAPENTADOL METHADONE My favorite drug because….? METHADONE- INDICATIONS • FDA labeled indications – (1) chronic pain (2) detoxification Oral soluble tablets for suspension NOT indicated for chronic pain treatment • Initial inpatient detoxification of opioids by a licensed trained provider with methadone and supportive care is appropriate • Methadone maintenance provider must have special credentialing and training as required by state Outpatient prescription must be for pain ONLY and say “for pain” on RX • Continuation of methadone maintenance from outside provider while patient is inpatient for another condition is appropriate http://cdn.atforum.com/wp-content/uploads/SAMHSA-2015-Guidelines-for-OTPs.pdf MECHANISM OF ACTION • Potent µ-opioid agonist • NMDA receptor antagonist • Norepinephrine reuptake inhibitor • Serotonin reuptake inhibitor ADVERSE EVENTS
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]